Molecular Modeling of Benzothiazepine Binding in the L-type Calcium Channel*
暂无分享,去创建一个
[1] W. Stühmer,et al. Calcium channel characteristics conferred on the sodium channel by single mutations , 1992, Nature.
[2] H. L. Yale. The trifluoromethyl group in medicinal chemistry. , 1959, Journal of medicinal and pharmaceutical chemistry.
[3] K. Seydl,et al. The benzazepine/benzothiazepine binding domain of the cardiac L-type Ca2+ channel is accessible only from the extracellular side , 1993, Pflügers Archiv.
[4] H. Scheraga,et al. Monte Carlo-minimization approach to the multiple-minima problem in protein folding. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[5] G. Breithardt,et al. Molecular site of action of the antiarrhythmic drug propafenone at the voltage-operated potassium channel Kv2.1. , 2003, Molecular pharmacology.
[6] J. Hume,et al. Interactions of organic calcium channel antagonists with calcium channels in single frog atrial cells , 1985, The Journal of general physiology.
[7] W. Almers,et al. Non‐selective conductance in calcium channels of frog muscle: calcium selectivity in a single‐file pore. , 1984, The Journal of physiology.
[8] M. Lazdunski,et al. Characterization of the Ca2+ coordination site regulating binding of Ca2+ channel inhibitors d-cis-diltiazem, (+/-)bepridil and (-)desmethoxyverapamil to their receptor site in skeletal muscle transverse tubule membranes. , 1985, Biochemical and biophysical research communications.
[9] Leonor Saiz,et al. Computer simulation studies of model biological membranes. , 2002, Accounts of chemical research.
[10] N. Dilmac,et al. Molecular Determinants of Frequency Dependence and Ca2+ Potentiation of Verapamil Block in the Pore Region of Cav1.2 , 2004, Molecular Pharmacology.
[11] R. MacKinnon,et al. Potassium channel receptor site for the inactivation gate and quaternary amine inhibitors , 2001, Nature.
[12] T. Nagao,et al. High-affinity binding of [3H]DTZ323 to the diltiazem-binding site of L-type Ca2+ channels. , 2003, European journal of pharmacology.
[13] B. Zhorov,et al. KvAP-based model of the pore region of shaker potassium channel is consistent with cadmium- and ligand-binding experiments. , 2005, Biophysical journal.
[14] P. Kollman,et al. An all atom force field for simulations of proteins and nucleic acids , 1986, Journal of computational chemistry.
[15] C. Strübing,et al. Extracellular localization of the benzothiazepine binding domain of L-type Ca2+ channels. , 1993, Molecular pharmacology.
[16] P. Focia,et al. Structural basis of TEA blockade in a model potassium channel , 2005, Nature Structural &Molecular Biology.
[17] D. Himmel,et al. Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. , 1988, The Journal of biological chemistry.
[18] U. Singh,et al. A NEW FORCE FIELD FOR MOLECULAR MECHANICAL SIMULATION OF NUCLEIC ACIDS AND PROTEINS , 1984 .
[19] H. Ichijo,et al. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists. , 2003, Molecular pharmacology.
[20] V. Ananthanarayanan,et al. Homology model of dihydropyridine receptor: implications for L-type Ca(2+) channel modulation by agonists and antagonists. , 2001, Archives of biochemistry and biophysics.
[21] Boris S. Zhorov,et al. A vector method for calculating the derivatives of the energy of the atom-atom interactions of complex molecules with respect to generalized coordinates , 1981 .
[22] J. Das,et al. Benzazepinone calcium channel blockers. 3. Synthesis and structure-activity studies of 3-alkylbenzazepinones. , 1992, Journal of medicinal chemistry.
[23] H. Glossmann,et al. Sequence Differences between α1C and α1S Ca2+ Channel Subunits Reveal Structural Determinants of a Guarded and Modulated Benzothiazepine Receptor* , 1999, The Journal of Biological Chemistry.
[24] H. Fozzard,et al. Modeling of the outer vestibule and selectivity filter of the L-type Ca2+ channel. , 2001, Biochemistry.
[25] Molecular Mechanism of Diltiazem Interaction with L-type Ca2+ Channels* , 1998, The Journal of Biological Chemistry.
[26] T. Linn,et al. Temperature‐dependent regulation of d‐cis‐[3H]diltiazem binding to Ca2+ channels by 1,4‐dihydropyridine channel agonists and antagonists , 1983, FEBS Letters.
[27] W. Almers,et al. The Ca channel in skeletal muscle is a large pore. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[28] S. Grissmer,et al. Investigation of the Phenylalkylamine Binding Site in hKv1.3 (H399T), a Mutant with a Reduced C-Type Inactivated State , 2005, Molecular Pharmacology.
[29] N. Dilmac,et al. Molecular determinants of Ca2+ potentiation of diltiazem block and Ca2+-dependent inactivation in the pore region of cav1.2. , 2003, Molecular pharmacology.
[30] G. Kaczorowski,et al. Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors. , 1986, The Journal of biological chemistry.
[31] J. Das,et al. Benzazepinone calcium channel blockers. 5. Effects on antihypertensive activity associated with N1 and aromatic substituents. , 1992, Journal of medicinal chemistry.
[32] B. Zhorov,et al. Atomic determinants of state‐dependent block of sodium channels by charged local anesthetics and benzocaine , 2006, FEBS letters.
[33] M. Cadene,et al. X-ray structure of a voltage-dependent K+ channel , 2003, Nature.
[34] B. Chait,et al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. , 1998, Science.
[35] M. Karplus,et al. Effective energy function for proteins in solution , 1999, Proteins.
[36] Ming Zhou,et al. A mutant KcsA K(+) channel with altered conduction properties and selectivity filter ion distribution. , 2004, Journal of molecular biology.
[37] W. Catterall,et al. Molecular determinants of drug binding and action on L-type calcium channels. , 1997, Annual review of pharmacology and toxicology.
[38] H. Lüllmann,et al. Frequency- and potential-dependency of the negative inotropic action of various dihydropyridine and non-dihydropyridine calcium antagonists. , 1992, Pharmacology & toxicology.
[39] I. Findlay. Physiological modulation of inactivation in L‐type Ca2+ channels: one switch , 2004, The Journal of physiology.
[40] J. Das,et al. Benzazepinone calcium channel blockers. 2. Structure-activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinones. , 1992, Journal of medicinal chemistry.
[41] Ettore Novellino,et al. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations. , 2007, Journal of medicinal chemistry.
[42] Benoît Roux,et al. A gate in the selectivity filter of potassium channels. , 2005, Structure.
[43] R. Tsien,et al. Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells , 1983, Nature.
[44] H. Fozzard,et al. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel. , 2003, Molecular pharmacology.
[45] G. Yellen,et al. Intracellular gate opening in Shaker K+ channels defined by high-affinity metal bridges , 2004, Nature.
[46] Boris S Zhorov,et al. Sodium channels: ionic model of slow inactivation and state-dependent drug binding. , 2007, Biophysical journal.
[47] B. Hille,et al. Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.
[48] H. Fozzard,et al. μ-Conotoxin Giiia Interactions with the Voltage-Gated Na+ Channel Predict a Clockwise Arrangement of the Domains , 2000, The Journal of general physiology.
[49] J. Das,et al. Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. , 1992, Journal of medicinal chemistry.
[50] N. Soldatov,et al. Molecular Determinants of Voltage-dependent Slow Inactivation of the Ca2+ Channel* , 2002, The Journal of Biological Chemistry.
[51] B. Zhorov,et al. Potassium, sodium, calcium and glutamate‐gated channels: pore architecture and ligand action , 2004, Journal of neurochemistry.
[52] B. Zhorov,et al. Modeling P-loops domain of sodium channel: homology with potassium channels and interaction with ligands. , 2005, Biophysical journal.
[53] Daniel Borgis,et al. A coarse-grained protein-protein potential derived from an all-atom force field. , 2007, The journal of physical chemistry. B.
[54] S. Spergel,et al. 1-Benzazepin-2-one calcium channel blockers--VI. Receptor-binding model and possible relationship to desmethoxyverapamil. , 1993, Bioorganic & medicinal chemistry.
[55] Thomas Huber,et al. G protein-coupled receptors self-assemble in dynamics simulations of model bilayers. , 2007, Journal of the American Chemical Society.
[56] T. Nagao,et al. 1,5-benzothiazepine binding domain is located on the extracellular side of the cardiac L-type Ca2+ channel. , 1997, Molecular pharmacology.
[57] S. Grissmer,et al. Interaction of d-Tubocurarine with Potassium Channels: Molecular Modeling and Ligand Binding , 2006, Molecular Pharmacology.